Insulin Manufacturers and PBMs Sued by State of California in Pricing Practices Dispute

The US state of California has filed suit against three major pharmacy benefit managers (PBMs) and the three largest insulin manufacturers over practices meant to spike the price of insulin. The pharma companies, including Novo Nordisk, Eli Lilly, and Sanofi, are accused of colluding, while the PBMs are accused of designing rebates to encourage manufacturers to raise list prices.

According to Phil Taylor, “California Attorney General Rob Bonta (pictured above) said the conduct of the companies amounts to unlawful and deceptive business practices that violate the state’s unfair competition laws. The suit follows legal action over insulin pricing taken by other states, including Arkansas, Kansas, Mississippi, and Minnesota.”

To read more, click here.

(Source: PharmaPhorum, January 13^th, 2023)